Physician profile
Maurice J Wilson
NPI 1881601565
$361,734.09
in general payments reported to CMS, 2019-2025
7 companies · $60K in 2025
The $60K reported for 2025 was more than what 99% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108K · 2020: $12K · 2021: $66K · 2022: $66K · 2023: $23K · 2024: $26K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Consulting Fee: $31K · Travel and Lodging: $22K · Food and Beverage: $4,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,646.40 |
| Consulting Fee | $30,615.00 |
| Travel and Lodging | $21,954.16 |
| Food and Beverage | $4,755.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $360,090.94 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Glaukos Corporation | $467.00 | 2022-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Abbvie INC. | $418.33 | 2023-2024 | Vuity, Durysta |
| Bausch & Lomb Americas INC. | $282.80 | 2023-2025 | Infuse |
| Allergan, INC. | $215.79 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $134.23 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.